Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Iterum Therapeutics Plc (NASDAQ: ITRM) closed the day trading at $0.31 down -7.89% from the previous closing price of $0.34. In other words, the price has decreased by -$7.89 from its previous closing price. On the day, 1.05 million shares were traded. ITRM stock price reached its highest trading level at $0.3298 during the session, while it also had its lowest trading level at $0.3.
On March 15, 2021, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $2.50.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on June 02, 2020, whereas the target price for the stock was revised from $7 to $2.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 18 ’25 when Dunne Michael W. bought 6,000 shares for $0.37 per share. The transaction valued at 2,191 led to the insider holds 241,001 shares of the business.
Dunne Michael W. bought 15,000 shares of ITRM for $10,854 on Aug 08 ’25. The Director now owns 235,001 shares after completing the transaction at $0.72 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ITRM now has a Market Capitalization of 15092868 and an Enterprise Value of 39313608. For the stock, the TTM Price-to-Sale (P/S) ratio is 42.51. Its current Enterprise Value per Revenue stands at 100.804 whereas that against EBITDA is -2.034.
Stock Price History:
The Beta on a monthly basis for ITRM is 2.84, which has changed by -0.8347368 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, ITRM has reached a high of $2.10, while it has fallen to a 52-week low of $0.33. The 50-Day Moving Average of the stock is -39.67%, while the 200-Day Moving Average is calculated to be -62.44%.
Shares Statistics:
Over the past 3-months, ITRM traded about 963.15K shares per day on average, while over the past 10 days, ITRM traded about 695890 shares per day. A total of 52.79M shares are outstanding, with a floating share count of 52.37M. Insiders hold about 0.79% of the company’s shares, while institutions hold 2.52% stake in the company. Shares short for ITRM as of 1765756800 were 1757033 with a Short Ratio of 1.82, compared to 1763078400 on 1382494. Therefore, it implies a Short% of Shares Outstanding of 1757033 and a Short% of Float of 3.35.
Earnings Estimates
The dynamic stock of Iterum Therapeutics Plc (ITRM) is currently being evaluated by a team of 2.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.59 and -$0.73 for the fiscal current year, implying an average EPS of -$0.66. EPS for the following year is -$0.31, with 2.0 analysts recommending between -$0.24 and -$0.38.
Revenue Estimates
For the next quarter, 2 analysts are estimating revenue of $1.4M. There is a high estimate of $1.4M for the next quarter, whereas the lowest estimate is $1.4M. Based on 2 analysts’ estimates, the company’s revenue will be $9.38M in the next fiscal year. The high estimate is $10M and the low estimate is $8.75M.
